NVAX
NASDAQ HealthcareNovavax, Inc. - Common Stock
Biotechnology
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
๐ Market Data
| Price | $8.07 |
|---|---|
| Volume | 1,874,785 |
| Market Cap | 1.33B |
| Beta | 2.420 |
| RSI (14-Day) | 76.9 Overbought |
| 200-Day MA | $8.43 |
| 50-Day MA | $8.49 |
| 52-Week High | $11.97 |
| 52-Week Low | $6.20 |
| Forward P/E | -13.15 |
| Price / Book | -6.97 |
๐ฏ Investment Strategy Scores
NVAX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (92/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NVAX in your text
Paste any article, transcript, or post โ the tool will extract NVAX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.